ALB and neoplasm: After progressing on fourth-line therapy, the patient first switched to toripalimab in combination with albumin paclitaxel and obtained a PFS of 7 months, with a significantly longer effective time compared to the literature, which may be related to the induction of apoptosis of tumor cells by prior chemotherapeutic agents, increased release of tumor antigenic substances, removal of immunosuppression, modulation of immune response, and remodeling of the immune microenvironment, resulting in immune potentiation (29–34).